metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
versus sunitinib
	atezolizumab alone
	IMmotion-150 (At - PDL1>1%), 2018 Nat. Med. 2018; 24:749-757 BJU Int 2020 Jul;126(1):73-82. NCT01984242	RCT	mRCC - L1 - PDL1 positive	atezolizumab	sunitinib	unresectable advanced or mRCC with a component of clear cell histology and/or sarcomatoid histology not previously treated with any systemic agents for RCC. Patients had PDL1 >1%	54 / 60	some concern	inconclusive	inconclusive 3 % increase in progression or deaths (PFS) (PE)
	atezolizumab plus bevacizumab
	IMmotion-151 (PDL1 >1%), 2019 Lancet 2019; 393:2404-2415 Clin Cancer Res 2020; 26:2506-2514 NCT02420821	RCT	mRCC - L1 - PDL1 positive	atezolizumab plus bevacizumab	Sunitinib	patients with unresectable locally advanced or metastatic renal cell carcinoma with any component of clear cell or sarcomatoid histology	178 / 184	high	inconclusive	no statistically significant result
	IMmotion-150 (AtB - PDL1>1%), 2018 Nat. Med. 2018; 24:749-757 BJU Int 2020 Jul;126(1):73-82. NCT01984242	RCT	mRCC - L1 - PDL1 positive	atezolizumab with bevacizumab	sunitinib	unresectable advanced or mRCC with a component of clear cell histology and/or sarcomatoid histology not previously treated with any systemic agents for RCC. patients with PDL1 >1% positive only	50 / 60	some concern	suggested	inconclusive 36 % decrease in progression or deaths (PFS) (PE)
	avelumab plus axitinib
	JAVELIN Renal 101( PDL1>1%), 2019 N. Engl. J. Med. 2019; 380:1103-1115 Cancer Sci. 2020; 111:907-923 Nat Med 2020 Sep 7. Ann Oncol 2020 Aug;31(8):1030-1039. ESMO Open 2021 Apr 23;6(3):100101. NCT02684006	RCT	mRCC - L1 - PDL1 positive	Avelumab plus Axitinib	Sunitinib	patients with previously untreated advanced renal cell carcinoma (PDL1>1% population)	270 / 290	some concern	conclusif	suggested 31 % decrease in deaths (OS) (PE) demonstrated 39 % decrease in progression or deaths (PFS) (PE) suggested 38 % decrease in PFS (extension)